Joaquin Rullas

Global Health Medicines R&D
Tres Cantos, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

Journal: bioRxiv : the preprint server for biology

Published: January 13, 2025

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: October 17, 2024

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

Journal: Antimicrobial agents and chemotherapy

Published: January 23, 2023

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection.

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection.

Journal: Pharmaceutics

Published: November 03, 2022

The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.

The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.

Journal: Science translational medicine

Published: May 04, 2022

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.

Journal: ACS infectious diseases

Published: February 22, 2022

Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite.

Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite.

Journal: ACS infectious diseases

Published: March 21, 2020

X-ray-based virtual slicing of TB-infected lungs.

X-ray-based virtual slicing of TB-infected lungs.

Journal: Scientific reports

Published: May 12, 2019

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Journal: ACS medicinal chemistry letters

Published: May 06, 2019

Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis.

Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis.

Journal: Journal of medicinal chemistry

Published: November 21, 2018

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.

Journal: Journal of medicinal chemistry

Published: June 27, 2018

Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).

Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).

Journal: Journal of medicinal chemistry

Published: September 28, 2017

Showing 1-12 of 24

Last Updated: 09/26/2026